SecSonar.com

Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Lexicon Pharmaceuticals, Inc. (LXRX) is a Biotechnology company based in US with a market capitalization of $975M. Revenue grew 60.2% year-over-year and free cash flow was negative at -$67.9M. This page tracks LXRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 103 employees · IPO Apr 7, 2000

Valuation

Valuation & price

$2.23 · as of May 17, 2026 · -15.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

9.07

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.55$1.71$0.87Jul 25Dec 25Jul 26Jul 7, 25$0.87Jul 9, 25$1.07Jul 11, 25$1.08Jul 15, 25$1.15Jul 17, 25$1.35Jul 21, 25$1.23Jul 23, 25$1.21Jul 25, 25$1.10Jul 29, 25$1.07Jul 31, 25$1.07Aug 4, 25$1.12Aug 6, 25$1.15Aug 11, 25$1.04Aug 13, 25$1.11Aug 15, 25$1.24Aug 19, 25$1.16Aug 21, 25$1.17Aug 25, 25$1.13Aug 27, 25$1.13Aug 29, 25$1.10Sep 3, 25$1.08Sep 5, 25$1.09Sep 9, 25$1.13Sep 11, 25$1.11Sep 16, 25$1.10Sep 18, 25$1.22Sep 22, 25$1.16Sep 24, 25$1.33Sep 26, 25$1.40Sep 30, 25$1.35Oct 2, 25$1.38Oct 6, 25$1.55Oct 8, 25$1.43Oct 10, 25$1.49Oct 14, 25$1.46Oct 16, 25$1.47Oct 21, 25$1.44Oct 23, 25$1.40Oct 27, 25$1.39Oct 29, 25$1.33Oct 31, 25$1.38Nov 4, 25$1.33Nov 6, 25$1.43Nov 10, 25$1.42Nov 12, 25$1.54Nov 14, 25$1.49Nov 18, 25$1.47Nov 20, 25$1.32Nov 25, 25$1.41Nov 28, 25$1.43Dec 2, 25$1.34Dec 4, 25$1.42Dec 8, 25$1.39Dec 10, 25$1.32Dec 12, 25$1.30Dec 16, 25$1.20Dec 18, 25$1.18Dec 22, 25$1.22Dec 24, 25$1.23Dec 29, 25$1.17Jan 2, 26$1.14Jan 6, 26$1.14Jan 8, 26$1.18Jan 12, 26$1.18Jan 14, 26$1.24Jan 16, 26$1.37Jan 21, 26$1.56Jan 23, 26$1.70Jan 27, 26$1.71Jan 29, 26$1.44Feb 2, 26$1.25Feb 4, 26$1.27Feb 9, 26$1.20Feb 11, 26$1.37Feb 13, 26$1.31Feb 18, 26$1.32Feb 20, 26$1.47Feb 24, 26$1.48Feb 26, 26$1.50Mar 2, 26$1.56Mar 4, 26$1.63Mar 6, 26$1.71Mar 10, 26$1.66Mar 12, 26$1.72Mar 17, 26$1.62Mar 19, 26$1.62Mar 23, 26$1.64Mar 25, 26$1.68Mar 27, 26$1.65Mar 31, 26$1.56Apr 2, 26$1.59Apr 7, 26$1.60Apr 9, 26$1.76Apr 13, 26$1.71Apr 15, 26$1.86Apr 17, 26$1.87Apr 22, 26$1.82Apr 24, 26$1.68Apr 28, 26$1.66Apr 30, 26$1.61May 4, 26$1.60May 6, 26$1.60May 8, 26$2.00May 12, 26$2.41May 14, 26$2.33May 18, 26$2.14May 20, 26$2.21May 22, 26$2.16May 28, 26$2.21Jun 1, 26$2.07Jun 3, 26$1.85Jun 5, 26$1.91Jun 9, 26$1.88Jun 11, 26$1.89Jun 15, 26$1.96Jun 17, 26$2.04Jun 22, 26$2.15Jun 24, 26$2.22Jun 26, 26$2.55Jul 2, 26$2.28
$0.8752-week range$2.64
Loading valuation history…

Fundamentals

Key fundamentals

$975M

Market cap

60.2%

Revenue growth (YoY)

99.5%

Gross margin

-$67.9M

Free cash flow (USD)

-$34M

Net debt

Net cash position

13.4%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$83.3MFY 2017$90.3MFY 2018$63.2MFY 2019$322.1MFY 2020$24.0MFY 2021$298.0KFY 2022$139.0KFY 2023$1.2MFY 2024$31.1MFY 2025$49.8M
$83.3M$49.8M

Free cash flow by year

2016 → 2025

FY 2016$-175.9MFY 2017$-185.6MFY 2018$-148.7MFY 2019$113.7MFY 2020$-143.1MFY 2021$-88.2MFY 2022$-90.2MFY 2023$-162.4MFY 2024$-179.8MFY 2025$-67.9M
-$175.9M-$67.9M

Gross margin by year

2021 → 2025

FY 2021-18371.8%FY 2022-37681.3%FY 2023-4798.0%FY 202498.0%FY 202599.5%
-18371.8%99.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventLoan AgreementMay 6, 2026Filing
  • 8-K eventPreferred Stock ConversionApr 30, 2026Filing

Questions

Frequently asked questions

What is Lexicon Pharmaceuticals, Inc.'s market cap?

Lexicon Pharmaceuticals, Inc. (LXRX) has a market capitalization of $975M.

What is LXRX's P/E ratio?

A meaningful P/E ratio is not available for LXRX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LXRX's price-to-book (P/B) ratio?

LXRX trades at 9.07 times book value per share.

Are insiders buying LXRX stock?

SEC Form 4 filings show no open-market insider buys at Lexicon Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

MGTX

MeiraGTx Holdings plc

$962.2M

PHAR

Pharming Group N.V.

$942.8M

ABUS

Arbutus Biopharma Corporation

$922.5M

SPRY

ARS Pharmaceuticals, Inc.

$908.6M

KURA

Kura Oncology, Inc.

$900.2M

JANX

Janux Therapeutics, Inc.

$894.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.